JO3400B1 - مركب صيدلاني من كاربيتوسين - Google Patents

مركب صيدلاني من كاربيتوسين

Info

Publication number
JO3400B1
JO3400B1 JOP/2011/0297A JOP20110297A JO3400B1 JO 3400 B1 JO3400 B1 JO 3400B1 JO P20110297 A JOP20110297 A JO P20110297A JO 3400 B1 JO3400 B1 JO 3400B1
Authority
JO
Jordan
Prior art keywords
carbetocin
pharmaceutical compound
pharmaceutical
compound
relates
Prior art date
Application number
JOP/2011/0297A
Other languages
English (en)
Inventor
Wisniewski Kazimierz
Nilsson Anders
Malm Mattias
Siekmann Britta
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43478408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3400(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Application granted granted Critical
Publication of JO3400B1 publication Critical patent/JO3400B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات صيدلانية ذات إستقرارية محسنة.
JOP/2011/0297A 2010-09-30 2011-09-28 مركب صيدلاني من كاربيتوسين JO3400B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10251690 2010-09-30

Publications (1)

Publication Number Publication Date
JO3400B1 true JO3400B1 (ar) 2019-10-20

Family

ID=43478408

Family Applications (3)

Application Number Title Priority Date Filing Date
JOP/2011/0297A JO3400B1 (ar) 2010-09-30 2011-09-28 مركب صيدلاني من كاربيتوسين
JOP/2018/0103A JOP20180103B1 (ar) 2010-09-30 2018-11-12 التركيب الصيدلاني للكاربيتوسين
JOP/2018/0102A JOP20180102B1 (ar) 2010-09-30 2018-11-12 مركب صيدلاني

Family Applications After (2)

Application Number Title Priority Date Filing Date
JOP/2018/0103A JOP20180103B1 (ar) 2010-09-30 2018-11-12 التركيب الصيدلاني للكاربيتوسين
JOP/2018/0102A JOP20180102B1 (ar) 2010-09-30 2018-11-12 مركب صيدلاني

Country Status (27)

Country Link
US (4) US9566311B2 (ar)
EP (5) EP3936117A1 (ar)
JP (2) JP6038797B2 (ar)
KR (2) KR101919119B1 (ar)
CN (4) CN104906032A (ar)
AU (1) AU2011309762B2 (ar)
BR (2) BR112013007362B1 (ar)
CA (1) CA2812510A1 (ar)
CY (2) CY1119245T1 (ar)
DK (4) DK4374878T3 (ar)
ES (4) ES2637988T3 (ar)
FI (1) FI4374878T3 (ar)
HR (3) HRP20250382T1 (ar)
HU (4) HUE056835T2 (ar)
IL (3) IL225238B (ar)
JO (3) JO3400B1 (ar)
LT (3) LT3222272T (ar)
MX (3) MX395271B (ar)
NZ (1) NZ609719A (ar)
PL (4) PL3222272T3 (ar)
PT (4) PT2621468T (ar)
RS (3) RS66759B1 (ar)
RU (2) RU2737264C2 (ar)
SI (4) SI3222272T1 (ar)
SM (3) SMT202200034T1 (ar)
TW (6) TWI680773B (ar)
WO (1) WO2012042371A2 (ar)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
WO2013169194A1 (en) * 2012-05-08 2013-11-14 Dilafor Ab Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent
HRP20240166T1 (hr) * 2014-09-19 2024-04-26 Ferring B.V. Postupak liječenja prader-willijevog sindroma
EP3200764B1 (en) * 2014-10-01 2020-07-22 Oxytone Bioscience B.V. Orally disintegrating solid pharmaceutical dosage unit containing a partus control substance
RU2701199C2 (ru) 2014-10-01 2019-09-25 Окситон Байосайенс Б.В. Перорально распадающаяся твердая фармацевтическая единица дозирования, содержащая контролирующее родовую деятельность вещество
US11389473B2 (en) 2015-01-07 2022-07-19 Tonix Pharmaceuticals Holding Corp. Magnesium-containing oxytocin formulations and methods of use
WO2016162819A1 (en) * 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody
MX2018012351A (es) 2016-04-12 2019-02-07 Trigemina Inc Formulaciones de oxitocina que contienen magnesio y metodos de uso.
CN107773531B (zh) * 2016-08-31 2021-05-04 成都倍特药业股份有限公司 一种马来酸麦角新碱注射液
CN108236601B (zh) * 2016-12-23 2020-04-17 深圳翰宇药业股份有限公司 一种稳定的含卡贝缩宫素的阴道给药的药用组合物及其制备方法
US10981955B2 (en) * 2017-08-11 2021-04-20 Ferring B.V. Method of manufacturing a pharmaceutical composition
GB201721846D0 (en) * 2017-12-22 2018-02-07 Arecor Ltd Novel composition
WO2019169342A1 (en) 2018-03-01 2019-09-06 Trigemina, Inc. Labeled oxytocin and method of manufacture and use
CN108721598B (zh) * 2018-07-03 2020-06-05 北京市新里程医药科技有限公司 一种缩宫素原料的制备方法及其药物组合物和制剂
US20200093884A1 (en) * 2018-09-20 2020-03-26 Mark C. Manning Stable intranasal formulations of carbetocin
WO2020061416A1 (en) * 2018-09-20 2020-03-26 Levo Therapeutics, Inc. Carbetocin drug product and process for preparing same
CN109745544B (zh) * 2018-11-23 2024-11-08 南京新百药业有限公司 稳定的缩宫素药物组合物及其制备方法
WO2020128499A1 (en) * 2018-12-21 2020-06-25 Arecor Limited Novel composition
JP7390031B2 (ja) * 2018-12-27 2023-12-01 国立大学法人金沢大学 オキシトシン誘導体及びその使用
KR20220011697A (ko) 2019-05-22 2022-01-28 바이오비에 아이앤씨. 테를리프레신 제형
CN110308222A (zh) * 2019-07-17 2019-10-08 武汉赛沃医药科技有限公司 一种卡贝缩宫素原料药有关物质检测方法
CN110403904A (zh) * 2019-07-26 2019-11-05 翔宇药业股份有限公司 卡贝缩宫素注射液及其应用
CN110237230A (zh) * 2019-07-31 2019-09-17 南京康舟医药科技有限公司 一种卡贝缩宫素药物组合物及其制备方法
MX2021015732A (es) * 2019-11-04 2022-01-24 Ferring Bv Administracion intranasal de merotocina para mejorar la lactancia.
CN111012739A (zh) * 2019-12-04 2020-04-17 长春圣金诺生物制药有限公司 一种可以常温储存的含卡贝缩宫素及稳定剂的注射液
CA3214303A1 (en) 2021-03-26 2022-09-29 Ot4B Treatment of dysphagia
CN114191388B (zh) * 2021-12-27 2023-06-09 苏州天马医药集团天吉生物制药有限公司 一种卡贝缩宫素制剂的制备方法
CN114712483B (zh) * 2022-05-12 2023-09-29 成都倍特药业股份有限公司 一种麦角新碱缩宫素复方注射液及其制备方法和用途
EP4687859A2 (en) 2023-04-04 2026-02-11 Tulex Pharmaceuticals, Inc. Desmopressin oral compositions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
CN1109558A (zh) * 1994-11-07 1995-10-04 马文亮 装有压力表的双管气筒
SE9604341D0 (sv) * 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
DK0916347T3 (da) 1997-11-18 2003-04-22 Uni Pharma Kleon Tsetis A B E Farmaceutiske injicerbare opløsninger der indeholder paracetamol og kombinationer af paracetamol med andre aktive bestanddele
US6333313B1 (en) 1998-10-29 2001-12-25 Board Of Regents, The University Of Texas System Clinical use of oxytocin alone or in combination to treat bone disorders
US20070032410A1 (en) * 2000-01-11 2007-02-08 Atossa Healthcare, Inc. Compositions and methods for the treatment of psychiatric disorders
US6894026B1 (en) * 2000-01-11 2005-05-17 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
JP2001233787A (ja) * 2000-02-04 2001-08-28 Patents Exploitation Co Bv 小・中サイズのペプチド含有薬学的組成物
AT409081B (de) * 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
ES2392073T3 (es) 2001-11-08 2012-12-04 Abbott Biotherapeutics Corp. Formulación farmacéutica líquida estable de anticuerpos IGG
EP1556068B1 (en) 2002-10-03 2010-08-18 Neuropharmacology Services, LLC Oxytocin for use in the treatment of Autism and Asperger's disorder
DK1599222T3 (da) 2003-01-08 2009-04-27 Novartis Vaccines & Diagnostic Stabiliserede vandige pr parater omfattende v vsfaktorvej-inhibitor (TFPI) eller v vsfaktorvej-inhibitorvariant
CN1938040A (zh) 2003-03-05 2007-03-28 Pr药品有限公司 缩宫素控释制剂及其应用方法
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
US20100311655A1 (en) * 2007-06-07 2010-12-09 Mdrna, Inc. Intranasal carbetocin formulations and methods for the treatment of autism
SI2178386T1 (sl) 2007-07-02 2011-01-31 Sime Darby Malaysia Berhad Sestavek maščobe za cvrtje
ES2319054B1 (es) 2007-08-06 2010-02-12 Gp Pharm S.A. Composicion farmaceutica oral de desmopresina.
DK2260053T3 (da) * 2008-03-31 2014-06-23 Ferring Bv Oxytocin-analoger
KR101419583B1 (ko) * 2008-10-15 2014-07-25 인타르시아 세라퓨틱스 인코포레이티드 고농축 약물 입자, 제형, 현탁액 및 이들의 용도

Also Published As

Publication number Publication date
SI4374878T1 (sl) 2025-06-30
EP4374878A2 (en) 2024-05-29
BR112013007362A2 (pt) 2016-07-12
EP3936117A1 (en) 2022-01-12
PL2621468T3 (pl) 2017-11-30
DK3222272T3 (da) 2022-01-24
CN103124554A (zh) 2013-05-29
LT4374878T (lt) 2025-04-25
TWI661834B (zh) 2019-06-11
ES3027637T3 (en) 2025-06-16
IL245328A0 (en) 2016-06-30
LT2621468T (lt) 2017-11-27
BR122021001123B1 (pt) 2021-05-18
CA2812510A1 (en) 2012-04-05
BR112013007362B1 (pt) 2021-05-25
DK2621468T3 (en) 2017-09-11
CN107080832B (zh) 2021-05-07
TWI532507B (zh) 2016-05-11
CN104906032A (zh) 2015-09-16
CN107080832A (zh) 2017-08-22
NZ609719A (en) 2014-07-25
RS56220B1 (sr) 2017-11-30
MX395271B (es) 2025-03-21
PL4374878T3 (pl) 2025-06-09
HUE056835T2 (hu) 2022-03-28
US20130210746A1 (en) 2013-08-15
TWI746951B (zh) 2021-11-21
PT3246018T (pt) 2022-01-13
RU2016143751A (ru) 2018-12-18
JP6250770B2 (ja) 2017-12-20
DK3246018T3 (da) 2022-01-17
AU2011309762B2 (en) 2014-07-17
KR20180123599A (ko) 2018-11-16
SMT201700420T1 (it) 2017-11-15
PT2621468T (pt) 2017-09-08
WO2012042371A2 (en) 2012-04-05
KR101919119B1 (ko) 2018-11-15
AU2011309762A1 (en) 2013-04-04
CN107412728A (zh) 2017-12-01
TWI680773B (zh) 2020-01-01
US20230124105A1 (en) 2023-04-20
JP2013543492A (ja) 2013-12-05
HUE034367T2 (en) 2018-02-28
EP3222272A1 (en) 2017-09-27
EP3222272B1 (en) 2021-11-03
ES2905561T3 (es) 2022-04-11
KR102102664B1 (ko) 2020-04-22
EP3246018B1 (en) 2021-11-03
JOP20180103A1 (ar) 2019-01-30
SMT202200034T1 (it) 2022-03-21
JOP20180103B1 (ar) 2022-03-15
RU2737264C2 (ru) 2020-11-26
RU2604690C2 (ru) 2016-12-10
TW202112389A (zh) 2021-04-01
US20170106044A1 (en) 2017-04-20
TW201605466A (zh) 2016-02-16
JP2017048226A (ja) 2017-03-09
SI2621468T1 (sl) 2017-10-30
PL3246018T3 (pl) 2022-05-02
TWI650134B (zh) 2019-02-11
HUE070972T2 (hu) 2025-07-28
MX352949B (es) 2017-12-15
TWI750934B (zh) 2021-12-21
PL3222272T3 (pl) 2022-03-07
EP4374878B1 (en) 2025-02-12
RU2016143751A3 (ar) 2020-01-16
ES2902418T3 (es) 2022-03-28
JOP20180102B1 (ar) 2022-03-15
IL245326B (en) 2021-04-29
CY1119245T1 (el) 2018-02-14
HRP20250382T1 (hr) 2025-05-23
JOP20180102A1 (ar) 2019-01-30
SI3246018T1 (sl) 2022-02-28
HUE057187T2 (hu) 2022-04-28
SMT202500165T1 (it) 2025-05-12
EP2621468B1 (en) 2017-06-14
FI4374878T3 (fi) 2025-05-16
SI3222272T1 (sl) 2022-01-31
HK1246170A1 (en) 2018-09-07
TW201605465A (zh) 2016-02-16
RU2013112666A (ru) 2014-11-10
HRP20171256T1 (hr) 2017-10-20
ES2637988T3 (es) 2017-10-18
LT3222272T (lt) 2021-12-27
US9566311B2 (en) 2017-02-14
MX2013003365A (es) 2013-07-29
US20170106043A1 (en) 2017-04-20
MX390779B (es) 2025-03-21
TW201729797A (zh) 2017-09-01
TW201940188A (zh) 2019-10-16
EP2621468A2 (en) 2013-08-07
RS66759B1 (sr) 2025-05-30
KR20130136467A (ko) 2013-12-12
HRP20211969T1 (hr) 2022-03-18
CY1124924T1 (el) 2023-01-05
PT4374878T (pt) 2025-05-02
EP3246018A1 (en) 2017-11-22
IL245326A0 (en) 2016-06-30
PT3222272T (pt) 2022-01-27
TW201219051A (en) 2012-05-16
IL225238A0 (en) 2013-06-27
WO2012042371A3 (en) 2013-04-04
RS62873B1 (sr) 2022-02-28
DK4374878T3 (da) 2025-05-05
IL245328B (en) 2022-04-01
EP4374878A3 (en) 2024-07-24
JP6038797B2 (ja) 2016-12-07
IL225238B (en) 2018-07-31

Similar Documents

Publication Publication Date Title
CY1124924T1 (el) Φαρμακευτικη συνθεση καρβετοκινης
UA108101C2 (xx) Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів
EA201290772A1 (ru) Новые формы ивабрадина гидрохлорида
EA201590534A1 (ru) Новые бициклические производные
EA201490037A1 (ru) Антагонисты trpv4
EA201270257A1 (ru) Производные n1-сульфонил-5-фторпиримидинона
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
IN2014DN09346A (ar)
CR20130045A (es) Compuestos terapéuticos
EA201490567A1 (ru) Новые бициклические производные дигидрохинолин-2-она
EA201590887A1 (ru) Композиция
CR20150271A (es) Peptidos como agonistas de oxitocina
EA033811B1 (ru) Стабильные бесконсервантные мидриатические и противовоспалительные растворы для инъекций
EA201290642A1 (ru) Соединения и способы
EA201490846A1 (ru) Новые производные арилхинолина
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
EP2557919A4 (en) STABILIZED FORMULATIONS OF STATIN
EA201270255A1 (ru) 5-фтор-2-оксопиримидин-1(2h)-карбоксилатные производные
EA201270256A1 (ru) Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида
EA201300034A1 (ru) Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения
EA201590787A1 (ru) Замещенные пиридопиразины в качестве ингибиторов syk
ITTO20110268A1 (it) Composizione di maquillage.
CR20140531A (es) Derivados de ariletinilo
EA201492280A1 (ru) Стабильный состав пексиганана
EA201391643A1 (ru) Составы с замедленным высвобождением парацетамола